Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough Licensing Toyama Antibiotic Garenoxacin, Picking Up Where Bristol Left Off

This article was originally published in The Pink Sheet Daily

Executive Summary

In-licensing of the quinolone will help fill Schering’s pipeline gap and build its anti-infectives portfolio. Toyama previously licensed the drug to Bristol, which returned rights five months ago. NDA submission will be based on completed Phase III studies in respiratory, skin and skin structure, and abdominal infections.

You may also be interested in...



Schering-Plough Pulls Garenoxacin Application In Europe

Action comes one year after the company withdrew an NDA for the antibiotic in the U.S.

Schering-Plough Pulls Garenoxacin Application In Europe

Action comes one year after the company withdrew an NDA for the antibiotic in the U.S.

Schering-Plough Drops Garenoxacin NDA, But Leaves Door Open For Resubmission

Sept. 11 advisory committee meeting on antibiotic cancelled.

Related Content

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel